XCR1 and neoplasm: First, we blocked the extravasation of myeloid cells (including DC) by means of a CD11b-blocking antibody (32, 33) and found that this manipulation depleted the cDC2 population in blood, tumors and tumor-draining lymph nodes (Fig. S9A), but did not change the number of cDC1 cells (which are CD11b- as illustrated in the gating strategy in Fig. S6) (16) in the blood, but prevented cDC1 cells and in particular migratory XCR1+ cDC1 cells from entering the tumor bed and (partially) the tumor-draining lymph nodes (Fig. S9B,C).